Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07709000 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 4 to 5
  2. Start date pushed from Sep 25, 2026 to Oct 9, 2026
  3. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Study sites: 3 to 4 · Start date: Sep 11, 2026 to Sep 25, 2026 · Eligibility criteria expanded, about 15 words Show 3 more changesShow less
    • Study sites: 3 to 4
    • Start date: Sep 11, 2026 to Sep 25, 2026
    • Eligibility criteria expanded, about 15 words
  4. Trial sites expanded: 0 → 3 locations Start date: Aug 21, 2026 to Sep 11, 2026v2 Show 1 more changeShow less
    • Start date: Aug 21, 2026 to Sep 11, 2026
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
Trial Details
NCT Number NCT07709000
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov